Abstract
In the RE-LY trial, a large randomized, controlled study of patients with nonvalvular atrial fibrillation (AF), 150 mg of dabigatran was superior to
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have